3-Aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms

Journal of Medicinal Chemistry

Volumn 49, Issue 22, 2006, Pages 6435-6438

  Ellsworth, Edmund L ^a   Tran, Tuan P ^a   Showalter, H D Hollis ^a   Sanchez, Joseph P ^a   Watson, Brian M ^a   Stier, Michael A ^a   Domagala, John M ^a   Gracheck, Stephen J ^a   Joannides, E Themis ^a   Shapiro, Martin A ^a   Dunham, Steve A ^a   Hanna, Debra L ^a   Huband, Michael D ^a   Gage, Jeffrey W ^a   Bronstein, Joel C ^a   Liu, Jia Yeu ^a   Nguyen, Dai Q ^b   Singh, Rajeshwar ^b  

^a PFIZER INC   (United States)

^b NAEJA Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOQUINAZOLINEDIONE; ANTIBIOTIC AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; GARENOXACIN; GATIFLOXACIN; GYRASE INHIBITOR; LEVOFLOXACIN; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IC 50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750436245     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060505l     Document Type: Article

References (31)

1. (a) Ohno, A. Antimicrobial agents and drug-resistance mechanism. Infect, Control 2004, 13 (10), 1012-1017.
2. (b) Livermore, D. M. Bacterial resistance: Origins, epidemiology, and impact. Clin. Infect. Dis. 2003, 36 (Suppl. 1), 1058-4838.
3. (a) Sprandel, K. A.; Rodvold, K. A. Safety and tolerability of fluoroquinolones. Clinical Cornerstone 2003, (Suppl 3), S29-36.
4. (b) Drlica, K.; Zhao, X. DNA gyrase, toposiomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61, 377.
5. (c) Gootz T. D.; Brighty K. E. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Med. Res. Rev. 1996, 16 (5), 433-486.
6. (a) Hoepelman, I. New fluoroquinolones: levofloxacin, moxifloxacin, and gatifloxacin. Ned. Tijdschr. Geneeskd. 2004, 148 (43), 2115-2121.
7. (b) Yoo, B. K.; Triller, D. M.; Yong, C.-S.; Lodise, T. P. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory imfections. Ann. Pharmacother. 2004, 38 (7-8), 1226-1235.
8. (c) Dalhoff, A.; Schmitz, F.-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22 (4), 203-221.
9. Ince, D.; Zhang, X.; Silver, L. C.; Hooper, D. C. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of genenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 2002, 46 (11), 3370-3380.
10. Ferraro, M. J. The rise of fluoroquinolone resistance: Fact or fiction. J. Chemother. 2002, 14 (Suppl. 3), 31-41.
11. Projan, S. J. New (and not so new) antibacterial targets-from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2002, 2 (5), 513-522.
12. (a) Chu, D. T. Recent developments in macrolides and ketolides. Curr. Opin. Microbiol. 1999, 2, 467-474.
13. (b) Wise, R.; Andrews, J. M. In vitro activities of two glycyclines. Antimicrob. Agents Chemother. 1994, 38, 1096-1102.
14. (c) Sanders, C. C. β-lactamase stability and in vitro activity of oral chphalosporins against strains possessing will-characterized mechanisms of resistance. Antimicrob. Agents Chemother. 1989, 33, 1313-1317.
15. (d) Kahne, D.; Leimkuhler, C.; Lu, W.; Walsh, C. Glycopeptide and lipogylcopeptide antibiotics. Chem. Rev. 2005, 105, 425-448.
16. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 1503, 2000.
17. (b) Amegadzie, A. K.; Carey, M. E.; Domagala, J. M.; Huang, L.; Micetich, R. G.; Singh, R.; Stier, M. A.; Vaisburg, A.; Sanchez, J. P. Isoquinolones. PCT Int. Appl. WO 9819648, 1998.
18. Tran, T. P.; Ellsworth, E. L.; Stier, M. A.; Domagal, J. M.; Showalter, H. D. H.; Gracheck, S. J.; Shapiro, M. A., Joannides, T. E.; Sing, R. Synthesis and structural-activity relationships of 3-hydroxyquinazolinedione antibacterial agents. Bioorq. Med. Chem. Lett. 2004, 14, 4405-4409.
19. Wentland, M. P. Structure-activity relationships of fluoroquinolones. In The New Generation of Quinolones; Siporin, C., Heifetz, C. L., Domagala, J. M., Eds.; Marcel Dekker: New York, 1990; pp 1-43.
20. Tran, T. P.; Ellsworth, E. L.; Watson, B. M.; Sanchez, J. P.; Showalter, H. D. H.; Rubin, J. R.; Stier, M. A.; Yip, J.; Nguyen, D. Q.; Bird, P.; Singy, R. A facile synthesis of substituted 3-amino-1H-quinazoline-2,4-diones. J. Heterocycl. Chem. 2005, 42, 669-674.
21. Domagala, J. M.; Hanna, L. D.; Heifetz, C. L.; Hutt, M. P.; Mich, T. F.; Sanchez, J. P.; Solomon, M. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J. Med. Chem. 1986, 29 (3), 394-404.
22. Hooper, D. C. Emerging mechanisms of fluoroquinolone resistance. Emerging Infect. Dis. 2001, 7 (2), 337-341.
23. Hooper, D. C. Quinolone mode of action - new aspects. Drugs 1993, 45 (Suppl 3), 8-14.
24. Shen, L. L.; Pernet, A. G. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc. Natl. Acad. Sci. U.S.A. 1985, 82 (2), 307-11.
25. (a) Morrissey, I.; Hoshino, K.; Sato, K.; Yodshida, A.; Hayakawa, I.; Bures, M. G.; Shen, L. L. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents Chemother. 1996, 40 (8), 1775-1784.
26. (b) Critchlow, S. E.; Maxwell, A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry 1996, 35, 7387-7393.
27. (c) Hughs, J.; Mellows, G. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J. Antibiot. 1978, 4, 330-335.
28. Hughs, J.; Mellows, G. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J. Biochem. 1978, 176, 305-318.
29. Dunham, S. A.; Olson, E. Methods of identifying and characterizing mutations within bacterial DNA gyrase and fabI. PCT Int. Appl. WO 0024932, 2000.
30. Piddock, L. J. Mechanisms of fluoroquinolone resistance: an update. Drugs 1999, 58 (Suppl 2), 11-18.
31. Cohen, M. A.; Huband, M. D.; Yoder, S. L.; Gage, J. W.; Roland, G. E. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. J. Antimicrob. Chemother. 1998, 41, 605-614.